These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32492199)

  • 1. Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of COVID-19 patient with diarrhea.
    Carnevale S; Beretta P; Morbini P
    J Med Virol; 2021 Jan; 93(1):61-63. PubMed ID: 32492199
    [No Abstract]   [Full Text] [Related]  

  • 2. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
    Frishman WH
    Cardiol Rev; 2021 May-Jun 01; 29(3):109. PubMed ID: 33758124
    [No Abstract]   [Full Text] [Related]  

  • 3. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Barone F; Giacomelli A; Casalini G; Corbellino M; Lai A; Gori A; Antinori S
    J Antimicrob Chemother; 2024 Sep; 79(9):2400-2402. PubMed ID: 39073825
    [No Abstract]   [Full Text] [Related]  

  • 5. Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346
    [No Abstract]   [Full Text] [Related]  

  • 6. Update Alert 2: Remdesivir for Adults With COVID-19.
    Kaka AS; MacDonald R; Linskens EJ; Wilt TJ
    Ann Intern Med; 2021 Dec; 174(12):W114-W115. PubMed ID: 34606312
    [No Abstract]   [Full Text] [Related]  

  • 7. Kidney Transplantation and COVID-19.
    Merhi B; Gohh R
    R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
    [No Abstract]   [Full Text] [Related]  

  • 8. [Not Available].
    Wu PE; Morris AM
    CMAJ; 2021 Apr; 193(14):E495-E496. PubMed ID: 33824151
    [No Abstract]   [Full Text] [Related]  

  • 9. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
    Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
    Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
    Quek E; Tahir H; Kumar P; Hastings R; Jha R
    Br J Hosp Med (Lond); 2021 Mar; 82(3):1-9. PubMed ID: 33792391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
    [No Abstract]   [Full Text] [Related]  

  • 14. Remdesivir for patients with COVID-19.
    Wu PE; Morris AM
    CMAJ; 2021 Jan; 193(4):E125. PubMed ID: 33408097
    [No Abstract]   [Full Text] [Related]  

  • 15. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
    Ali S; Khalid S; Afridi M; Akhtar S; Khader YS; Akhtar H
    JMIR Public Health Surveill; 2021 May; 7(5):e27609. PubMed ID: 34009133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 reinfection.
    Romera I; Núñez K; Calizaya M; Baeza I; Molina R; Morillas J
    Med Intensiva (Engl Ed); 2021; 45(6):375-376. PubMed ID: 34294235
    [No Abstract]   [Full Text] [Related]  

  • 17. Remdesivir: a pendulum in a pandemic.
    Schwartz IS; Heil EL; McCreary EK
    BMJ; 2020 Nov; 371():m4560. PubMed ID: 33234523
    [No Abstract]   [Full Text] [Related]  

  • 18. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R
    Ann Intern Med; 2021 May; 174(5):673-679. PubMed ID: 33560862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
    Chua KP; Conti RM
    JAMA Intern Med; 2020 Oct; 180(10):1273-1274. PubMed ID: 32804187
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatments for COVID-19: where are we now?
    Mendes A
    Br J Community Nurs; 2020 Aug; 25(8):412-413. PubMed ID: 32757900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.